胃癌骨转移所致难治性癌性疼痛的镇痛治疗1例报告及文献复习.
Analgesic treatment for refractory cancer pain caused by gastric cancer bone metastasis: A case report and literature review.
发表日期:2024 Jul 12
作者:
Dan Wang, Ting Jiang, Lingli Zheng, Chaomin Liu, Xiaomei Fan, Yan Li, Jing Li
来源:
Bone & Joint Journal
摘要:
患有骨转移相关癌症疼痛的患者通常会经历多种复杂的疼痛类型。因此,使用多模式联合治疗至关重要。在监测疼痛治疗中常见不良反应的同时,警惕罕见但严重的血清素综合征也至关重要。一名 53 岁女性,患有转移性胃癌,因严重且不受控制的胸部和颈部疼痛住院。在滴定癌症止痛药过程中,她出现了血清素综合征。他被诊断为难治性癌痛和血清素综合征。分析了一位胃癌骨转移患者的癌症止痛药物的完整过程,重点关注了选择镇痛药物、调整阿片类药物剂量、预防和治疗药物相关不良反应。患者癌痛得到良好控制,不良反应得到及时处理。此外,通过调整用药方案,预防难以耐受的不良反应。在临床上,必须针对癌痛患者制定个性化镇痛方案,以提高患者用药依从性,预防严重不良反应的发生,提高整体治疗质量。癌症患者的生活。医疗保健专业人员应更加关注与阿片类药物相关的 ADR,而药剂师应协助他们及时识别 ADR。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版
Patients with bone metastasis-associated cancer pain often experience a complex mix of pain types. Consequently, the use of multimodal combination therapy is essential. While monitoring for common adverse reactions in pain treatment, it is also crucial to be vigilant for the rare but serious serotonin syndrome.A 53-year-old female with metastatic gastric cancer was hospitalized due to severe, uncontrolled thoracic and cervical pain. During the titration of her cancer pain medication, she developed serotonin syndrome.He was diagnosed with refractory cancer pain and serotonin syndrome.The complete process of cancer pain medication in a patient with gastric cancer and bone metastasis was analyzed, with a primary focus on the selection of analgesic medications, adjustment of opioid dosages, and prevention and treatment of medication-associated adverse reactions.The patient's cancer pain was well controlled, with the prompt management of adverse reactions. Furthermore, by adjusting the medication regimen, intolerable adverse reactions were prevented.In clinical settings, personalized analgesic regimens must be developed for patients with cancer pain to enhance patient compliance with medication, prevent the occurrence of severe adverse reactions, and improve the overall quality of life of patients with cancer. Healthcare professionals should pay increased attention to ADRs associated with opioid medications, whereas pharmacists should assist them in promptly identifying ADRs.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.